NEW YORK, Jan. 7-CuraGen is working with Pfizer to apply toxicogenomics screening and protein pathway mapping for the pharmaceutical company's drug candidates, CuraGen said today.
CuraGen researchers will use the company's Predictive Toxicogenomics Screen early on in the drug development process to select promising compounds. The company will also supply its protein pathway mapping techniques to explore mechanisms and activity of drugs in later development stages.
Financial details of the agreement were not disclosed.
For further information, see the press release.